Drugs Acting on Skin and Mucous Membrane

Classification

Topical corticosteroids(potency-ranked). Retinoids: tretinoin, isotretinoin, adapalene. Keratolytics: salicylic acid, urea. Topical antimicrobials(same mechanisms as systemic Antimicrobials topics — mupirocin, topical clindamycin/erythromycin for acne). Sunscreens: physical(zinc oxide, titanium dioxide) vs chemical(avobenzone, oxybenzone). Local irritants: capsaicin, methyl salicylate.

Topical Corticosteroids — Potency & Vehicle

Potency hierarchy(mild=hydrocortisone → super-potent=clobetasol) = receptor affinity + formulation. SAME receptor mechanism as systemic Corticosteroids, LOCAL application → local AE mirror systemic logic(skin atrophy, striae, telangiectasia = thinning connective tissue/impaired collagen synthesis AT SKIN LEVEL). Systemic absorption/HPA suppression = real but smaller risk, proportional to potency+surface area+OCCLUSION(dressing/skin folds → dramatically ↑percutaneous absorption, prevents evaporation+↑stratum corneum hydration) — same drug can shift “purely local” → “clinically meaningful systemic” purely by HOW applied.

VEHICLE independent variable: ointments(occlusive, greasy) > creams/lotions for penetration/potency at IDENTICAL steroid+concentration — “which steroid” and “how formulated” = 2 SEPARATE variables determining actual clinical potency.

Retinoids

Tretinoin(topical)/isotretinoin(oral): vitamin A derivatives, RAR/RXR nuclear receptors → normalize follicular keratinization(↓abnormal hyperkeratinization initiating comedones). Isotretinoin ALSO ↓sebaceous gland size/sebum directly — addresses ALL 4 acne pathogenesis factors(hyperkeratinization, sebum, P. acnes, inflammation) = MOST effective acne Rx, reserved severe/scarring/resistant given AE burden.

TERATOGENICITY = isotretinoin’s single most important risk — severe(craniofacial, cardiac, CNS malformations) → MANDATORY verified contraception+pregnancy testing before/during (structured risk-management programs, e.g. iPLEDGE) — HIGHEST-STAKES safeguard in topic, analogous seriousness to thalidomide(Antileprotic Drugs) but NO comparable “worth the risk” exception once pregnancy confirmed/possible. Other AE: mucocutaneous dryness(lips/skin/eyes — near-universal, reflects epithelial-turnover normalization body-wide), hypertriglyceridaemia, hepatotoxicity, debated mood/depression association(actively monitored despite unclear mechanism).

Sunscreens

Physical/mineral(zinc oxide, titanium dioxide): REFLECT/scatter UV → broad-spectrum(UVA+UVB), IMMEDIATE effect, better tolerated sensitive skin(minimal chemical absorption). Chemical(avobenzone, oxybenzone): ABSORB UV → re-emit as heat(photochemical) → needs ~20-30min after application for full effect(binding/organizing in outer skin layers) — practical counselling point often missed(applying right before sun exposure = materially less protection).

Keratolytics

Salicylic acid: dissolves intercellular cement(desmosomal connections) between corneocytes → controlled outer-layer shedding. Acne, warts, psoriasis, calluses — SAME “encourage shedding of abnormal/excess keratin” logic across different conditions. Large-surface-area absorption(esp children, occlusion) → genuine salicylate toxicity risk(SAME aspirin-family mechanism, Antiplatelet Drugs) — topical ≠ automatically free of systemic risk, esp large area/prolonged/occluded use.

Clinical Relevance

Recurring theme: topical administration REDUCES but doesn’t ELIMINATE systemic exposure risk — actual degree depends on formulation/application-specific factors(potency, vehicle occlusiveness, surface area, barrier integrity), NOT a fixed property of “topical” as a route. SAME corticosteroid mechanism, isotretinoin teratogenicity, salicylate toxicity mechanism already established for SYSTEMIC use all reappear here, modulated by how much topically-applied dose actually reaches systemic circulation under given application conditions.

Classification

Topical corticosteroids (classified by potency)
Retinoids: tretinoin, isotretinoin, adapalene
Keratolytics: salicylic acid, urea
Topical antimicrobials: already covered under the relevant systemic Antimicrobials topics where the same mechanism applies (mupirocin, topical clindamycin/erythromycin for acne)
Sunscreens: physical (zinc oxide, titanium dioxide) versus chemical (avobenzone, oxybenzone) UV filters
Local irritants/counterirritants: capsaicin, methyl salicylate

Topical Corticosteroids — Potency and the Vehicle Effect

Topical corticosteroids are ranked in a potency hierarchy (from mild — hydrocortisone — to super-potent — clobetasol) determined by the specific molecule’s receptor affinity and its formulation — the same receptor mechanism already described in full under Corticosteroids, here applied locally rather than systemically, meaning local adverse effects (skin atrophy, striae, telangiectasia) mirror the systemic adverse-effect logic (thinning connective tissue, impaired collagen synthesis) at the skin level specifically, while systemic absorption/HPA-axis suppression remains a real but generally much smaller risk than with oral/injected steroids — proportional to the potency used, the surface area treated, and specifically occlusion (covering the treated area, e.g. with a dressing or in skin folds, dramatically increases percutaneous absorption of any topical agent by preventing evaporation and increasing hydration of the stratum corneum) — a genuinely important, examined point that the same drug/formulation can shift from “purely local effect” to “clinically meaningful systemic absorption” purely based on how it’s applied, not just what’s applied. Vehicle matters independent of the steroid molecule itself: ointments (occlusive, greasy) enhance penetration/potency compared with creams or lotions of the identical steroid at the identical concentration, which is why the same molecule can appear at different potency tiers depending on its specific formulation — a specific, examined point that “which steroid” and “how it’s formulated” are two independent variables determining actual clinical potency.

Retinoids

Tretinoin (topical) and isotretinoin (oral): vitamin A derivatives acting on nuclear retinoic acid receptors (RAR/RXR), altering gene transcription to normalize follicular keratinization (reducing the abnormal follicular hyperkeratinization that initiates comedone formation in acne) and, for isotretinoin specifically, also reducing sebaceous gland size/sebum production directly — isotretinoin’s action on all four major acne pathogenesis factors (hyperkeratinization, sebum production, P. acnes proliferation, inflammation) is why it’s the most effective acne therapy available and reserved for severe/scarring/treatment-resistant acne rather than first-line use, given its adverse-effect burden. Teratogenicity is isotretinoin’s single most important, most stringently managed risk — a well-established, severe teratogen (causing craniofacial, cardiac, and CNS malformations), requiring mandatory, verified contraception and pregnancy testing before and during therapy in patients who could become pregnant (formalized in many jurisdictions as a structured risk-management program, e.g. iPLEDGE in the US) — the single highest-stakes prescribing safeguard in this entire topic, worth understanding as directly analogous in seriousness to thalidomide’s teratogenicity management already discussed under Antileprotic Drugs, though isotretinoin’s therapeutic use (unlike thalidomide’s ENL indication) has no comparable “worth the risk” exception once pregnancy is confirmed/possible. Other adverse effects: mucocutaneous dryness (lips, skin, eyes — a near-universal, expected effect reflecting the drug’s normalization of epithelial turnover throughout the body, not just the face), hypertriglyceridaemia, hepatotoxicity, and a debated, historically-flagged but not definitively established association with mood changes/depression (actively monitored during therapy given the seriousness of the concern even without full mechanistic clarity).

Sunscreens

Physical/mineral filters (zinc oxide, titanium dioxide): reflect and scatter UV radiation, providing broad-spectrum (UVA and UVB) protection immediately upon application, generally better tolerated in sensitive skin given minimal chemical absorption/reactivity. Chemical filters (avobenzone, oxybenzone, and others): absorb UV radiation and re-emit it as lower-energy (heat) radiation via a photochemical mechanism, requiring roughly 20–30 minutes after application before becoming fully effective (time needed for the chemical to properly bind/organize within the skin’s outer layers) — a specific, practically important point often missed in patient counselling (applying chemical sunscreen immediately before sun exposure provides materially less protection than applying it in advance).

Keratolytics

Salicylic acid: works by dissolving the intercellular cement (desmosomal connections) between corneocytes in the stratum corneum, promoting controlled shedding of the outer skin layer — used for acne, warts, psoriasis, and calluses, exploiting the same fundamental “encourage shedding of the abnormal/excess outer keratin layer” logic across genuinely different dermatologic conditions. Salicylate absorption through large treated surface areas (particularly in children, or with occlusion) carries a genuine, if uncommon, salicylate toxicity risk — the same aspirin-family toxicity already covered under Antiplatelet Drugs, worth recognizing that a topically-applied drug is not automatically free of systemic absorption risk, especially over a large surface area or with prolonged/occluded use.

Clinical Relevance

The recurring theme across this topic is that topical administration reduces but does not eliminate systemic exposure risk, and that the actual degree of systemic exposure depends on formulation-specific and application-specific factors (potency, vehicle occlusiveness, surface area treated, skin barrier integrity) rather than being a fixed property of “topical” as a route — the same corticosteroid receptor mechanism, teratogenicity risk (isotretinoin), and salicylate toxicity mechanism already established in other topics for systemic use all reappear here, simply modulated by how much of the topically-applied dose actually reaches the systemic circulation under a given set of application conditions.

Topical corticosteroid potency hierarchy with occlusion and vehicle (ointment vs cream) effects on percutaneous absorption marked as independent variables.
Isotretinoin’s action on all four acne pathogenesis factors compared to topical tretinoin’s narrower keratinization-only effect.